CLASS ACTION UPDATE for MU, AVEO, DPLO and AMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
Micron Technology Inc. (NASDAQGS: MU) Class Period: September 26, 2017 - November 19, 2018 Lead Plaintiff Deadline: March 25, 2019 Join the action: https://www.zlk.com/pslra-1/micron-technology-inc-loss-form?wire=3
Allegations: Micron Technology Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company engaged in anti-competitive behavior, including artificially restricting supply growth of DRAM; (2) these anti-competitive efforts were reasonably likely to lead to regulatory scrutiny; (3) the Company’s anti-competitive efforts artificially boosted its operating metrics; (4) as a result, the Company’s financial performance, including revenue, was overstated; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To learn more about the Micron Technology Inc. class action contact email@example.com.
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) Class Period: August 4, 2016 - January 31, 2019 Lead Plaintiff Deadline: April 26, 2019 Join the action: https://www.zlk.com/pslra-1/aveo-pharmaceuticals-inc-loss-form?wire=3
Allegations: During the class period, AVEO Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented in June 2013; (ii) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (iii) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (iv) as a result, AVEO’s public statements were materially false and misleading at all relevant times.
To learn more about the AVEO Pharmaceuticals, Inc. class action contact firstname.lastname@example.org.
Diplomat Pharmacy, Inc. (NYSE: DPLO) Class Period: February 26, 2018 - February 21, 2019 Lead Plaintiff Deadline: April 25, 2019 Join the action: https://www.zlk.com/pslra-1/diplomat-pharmacy-inc-loss-form?wire=3
Allegations: Diplomat Pharmacy, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) Diplomat had downplayed its success in integrating and growing its PBM business, which included LDI Integrated and National Pharmaceutical, two companies Diplomat had acquired in late 2017; (2) consequently, Diplomat would need to record a non-cash impairment charge upwards of approximately $630 million relating to its PBM business and these 2017 acquisitions; (3) due to the foregoing, Diplomat would withdraw its preliminary 2019 full-year outlook issued less than seven weeks prior; and (4) as a result, defendants’ statements about Diplomat’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
To learn more about the Diplomat Pharmacy, Inc. class action contact email@example.com.
Amarin Corporation (NASDAQGM: AMRN) Class Period: September 24, 2018 - November 9, 2018 Lead Plaintiff Deadline: April 23, 2019 Join the action: https://www.zlk.com/pslra-1/amarin-corporation-loss-form?wire=3
Allegations: Amarin Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin’s public statements were materially false and misleading at all relevant times.
To learn more about the Amarin Corporation class action contact firstname.lastname@example.org.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.55 Broadway, 10th FloorNew York, NY 10006 email@example.com Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171 www.zlk.com